Cell Lysis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Cell Lysis Market is Segmented by Product (Instruments and Reagents), Type of Cells (Mammalian Cells, Microbial Cells, and Plant Cells), End User (Biotechnology or Biopharmaceutical Companies, Research Laboratories and Academic Institutes, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

CAGR
Study Period: 2018-2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 8.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The cell lysis market was valued at approximately USD 3,560 million in 2020, and it is expected to reach USD 6,200 million by 2026, registering a CAGR of 8.5% during the forecast period, 2021-2026. The market is expected to grow due to the increasing expenditure in research and development, increasing application in the pharmaceutical and biopharmaceutical industries, and a rising focus on personalized medicine.

The severe respiratory consequences of the COVID-19 pandemic have prompted an urgent need for novel therapies that have increased the number of drug discoveries, thereby positively impacting the cell lysis market. There was increasing research found taking place; for instance, in May 2020, the Department of Biotechnology (DBT) in India undertook a project to sequence 1,000 SARS-CoV-2 genomes from samples to understand the evolving behavior of the virus that causes COVID-19. The samples were being collected across India to study the emerging mutations in the virus and how they change the symptoms of the disease. Therefore, all this increasing research has utilized different processes and increased the demand for systems and reagents. Therefore, the high adoption of cell lysis and disruption methods during downstream processing to manufacture bio-therapeutics and other animal-based recombinant products further boosts the overall market growth.

According to the GLOBOCAN, in 2020, there were around 19,292,789 new cases of cancer that were reported worldwide, while about 9,958,133 deaths occurred due to it.​Also, according to the World Cancer Research Fund, in 2018, there were 18 million cancer cases around the world. Lung and breast cancers were found to be the most common cancers globally. ​Furthermore, with the increase in the prevalence of infectious diseases and cancers, there is the utilization of cell samples for research and development of drugs, which is expected to lead to positive growth for the cell lysis market.

​Personalized medicine is found to be one of the latest developments of gene-related studies that provide custom-tailored treatments as per the specific needs of patients, which has massive significance in disease prevention, diagnosis, prognosis, and therapeutics. Protein or nucleic acid analysis is found to be most crucial to develop innovative solutions for clinical practices such as personalized medicines, where cell lysis holds a major role.

Furthermore, rising investments by various governments and private organizations in R&D related to biotechnological processes and academics are expected to further drive the market significantly.

Scope of the Report

As per the scope of the report, cell lysis is one of the major steps in biological research to remove the biological materials within and use them in various downstream applications to fulfill respective research goals. Cell lysis is used throughout many industries, from pharmaceuticals to food, cosmetics, and biotechnology. The cell lysis market is segmented by product (instruments and reagents), type of cells (mammalian cells, microbial cells, and plant cells), end user (biotechnology or biopharmaceutical companies, research laboratories and academic institutes, and other end users), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

By Type of Product
Instruments
Homogeniser
Centrifugation
Other Types of Products
Reagents
By Type of Cells
Mammalian Cells
Microbial Cells
Plant Cells
By End User
Biotechnology or Biopharmaceutical Companies
Research Laboratories and Academic Institutes
Other End Users
Geography
North America
United States (By Type of Product, Type of Cells, and End User)
Canada (By Type of Product, Type of Cells, and End User)
Mexico (By Type of Product, Type of Cells, and End User)
Europe
Germany (By Type of Product, Type of Cells, and End User)
United Kingdom (By Type of Product, Type of Cells, and End User)
France (By Type of Product, Type of Cells, and End User)
Italy (By Type of Product, Type of Cells, and End User)
Spain (By Type of Product, Type of Cells, and End User)
Rest of Europe (By Type of Product, Type of Cells, and End User)
Asia-Pacific
China (By Type of Product, Type of Cells, and End User)
Japan (By Type of Product, Type of Cells, and End User)
India (By Type of Product, Type of Cells, and End User)
Australia (By Type of Product, Type of Cells, and End User)
South Korea (By Type of Product, Type of Cells, and End User)
Rest of Asia-Pacific (By Type of Product, Type of Cells, and End User)
Middle-East and Africa
GCC (By Type of Product, Type of Cells, and End User)
South Africa (By Type of Product, Type of Cells, and End User)
Rest of Middle-East and Africa (By Type of Product, Type of Cells, and End User)
South America
Brazil (By Type of Product, Type of Cells, and End User)
Argentina (By Type of Product, Type of Cells, and End User)
Rest of South America (By Type of Product, Type of Cells, and End User)

Report scope can be customized per your requirements. Click here.

Key Market Trends

Instruments are Expected to be One of the Most Preferred Products for Cell Lysis in the Future

Instruments are tools or devices used to lyse the cells. They are further categorized as sonicators, homogenizers, French press, microfluidizer, and others. Instruments such as homogenizers and sonicators are used mostly for cell lysis/cell fractionation, and sonicators are found leading all the instruments owing to their increasing use in cell fractionation.

With the rise in COVID-19 spread, there are rising infectious diseases testing, increasing the demand for more drugs. With this, there has been an increase in cell processing procedures, thereby boosting the demand for instruments.

Common instruments such as a blender and the polytron homogenizer are found useful in extracting proteins from large amounts of complex mammalian tissue and in disrupting large volumes of yeast samples. These blenders are preferred for larger sample sizes and larger volumes, which has boosted the use of specialized instruments (e.g., a bead mill) that are being used to shake the container of samples and beads. Therefore, many instrument manufacturers have developed a variety of instruments to carry out cell lysis procedures.

With the rising number of chronic diseases and rising infectious diseases, there is a high demand in the research laboratories and institutes and biopharmaceutical and biotechnology companies that has helped in boosting the overall drug demand. The instruments can lyse cells and provide a high yield, maximize active compound, guarantee easy scalability, and are easy to clean (no unmounting to the cells). All these advantages have increased the demand for instruments that are involved in cell lysis procedures.

However, the commercial availability and reliability of tools that are used in cell disruption and lysis are boosting the growth of this segment.

Cancer Cases Reported Worldwide, 2020

North America Dominates the Market and is Expected to Continue to do so Over the Forecast Period

North America is spearheading the cell lysis market owing to the increasing expenditure in research and development and increasing incidence of chronic diseases.

With the rise in COVID-19, there was an increase in lab testing techniques, which was anticipated to intensify the progress of the cell lysis market. Furthermore, scientists researching COVID-19 cellular response and developing vaccines are creating a huge demand for cell lysis systems and reagents used to meet their research needs. Therefore, all this increasing research has had a positive impact on the market.

The increasing demand for cell-based therapy for the treatment of cancer is also expected to augment the growth of the cell lysis market. Also, the increasing prevalence and incidences of several diseases and rising research and development expenditure in the North American region are triggering the need for an advanced R&D scenario across all sectors of life sciences. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), 2018, US firms conduct over half the world's R&D in pharmaceuticals. Approximately USD 79.6 billion was invested in biopharmaceutical R&D in the United States in 2018. ​

Hence, the continuous growth of healthcare infrastructure in the United States and the increase in the patient population provide wider opportunities for clinical laboratories to expand, and this helps in boosting the market growth.

Cell Lysis Market- Growth Rate By Region

Competitive Landscape

The market studied is moderately competitive and consists of local and international companies. Some of the key players include Thermo Fisher Scientific Inc., Merck KGaA, F. Hoffmann-La Roche Ltd, Qiagen NV, Becton, Dickinson and Company, among others. These companies are found focused on novel product developments and acquisitions/collaborations to enhance their market positions. With the advancements in the pharmaceutical and biotechnology sector, few small to mid-sized companies are entering the market, and it is believed that these companies will hold a substantial share of the market studied in the future. Also, the competition is increasing due to the new product launches in this market.

Recent Developments

In April 2020, SPX FLOW launched two new APV Rannie and Gaulin homogenizer models to enhance productivity.

In May 2020, Aalto Bio Reagents Ltd launched the RNA lysis buffer reagent for the pre-treatment of COVID-19 samples prior to testing. This essential RNA Lysis buffer was produced by Aalto Bio due to the unavailability of similar reagents from other manufacturers in Europe.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Expenditure in Research and Development

      2. 4.2.2 Increasing Application in Pharmaceutical and Biopharmaceutical Industries

      3. 4.2.3 Rising Focus on Personalized Medicine

    3. 4.3 Market Restraints

      1. 4.3.1 Regulatory Compliance

      2. 4.3.2 Issues in Mechanical Process to Apply at the Microscale Level

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type of Product

      1. 5.1.1 Instruments

        1. 5.1.1.1 Homogeniser

        2. 5.1.1.2 Centrifugation

        3. 5.1.1.3 Other Types of Products

      2. 5.1.2 Reagents

    2. 5.2 By Type of Cells

      1. 5.2.1 Mammalian Cells

      2. 5.2.2 Microbial Cells

      3. 5.2.3 Plant Cells

    3. 5.3 By End User

      1. 5.3.1 Biotechnology or Biopharmaceutical Companies

      2. 5.3.2 Research Laboratories and Academic Institutes

      3. 5.3.3 Other End Users

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States (By Type of Product, Type of Cells, and End User)

        2. 5.4.1.2 Canada (By Type of Product, Type of Cells, and End User)

        3. 5.4.1.3 Mexico (By Type of Product, Type of Cells, and End User)

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany (By Type of Product, Type of Cells, and End User)

        2. 5.4.2.2 United Kingdom (By Type of Product, Type of Cells, and End User)

        3. 5.4.2.3 France (By Type of Product, Type of Cells, and End User)

        4. 5.4.2.4 Italy (By Type of Product, Type of Cells, and End User)

        5. 5.4.2.5 Spain (By Type of Product, Type of Cells, and End User)

        6. 5.4.2.6 Rest of Europe (By Type of Product, Type of Cells, and End User)

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China (By Type of Product, Type of Cells, and End User)

        2. 5.4.3.2 Japan (By Type of Product, Type of Cells, and End User)

        3. 5.4.3.3 India (By Type of Product, Type of Cells, and End User)

        4. 5.4.3.4 Australia (By Type of Product, Type of Cells, and End User)

        5. 5.4.3.5 South Korea (By Type of Product, Type of Cells, and End User)

        6. 5.4.3.6 Rest of Asia-Pacific (By Type of Product, Type of Cells, and End User)

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC (By Type of Product, Type of Cells, and End User)

        2. 5.4.4.2 South Africa (By Type of Product, Type of Cells, and End User)

        3. 5.4.4.3 Rest of Middle-East and Africa (By Type of Product, Type of Cells, and End User)

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil (By Type of Product, Type of Cells, and End User)

        2. 5.4.5.2 Argentina (By Type of Product, Type of Cells, and End User)

        3. 5.4.5.3 Rest of South America (By Type of Product, Type of Cells, and End User)

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 COMPANY PROFILES

      1. 6.1.1 Becton, Dickinson and Company

      2. 6.1.2 Bio-Rad Laboratories Inc.

      3. 6.1.3 Danaher Corporation

      4. 6.1.4 Eppendorf AG

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 Labfreez Instruments Group Co. Ltd

      7. 6.1.7 Merck KGaA

      8. 6.1.8 Qsonica LLC

      9. 6.1.9 Takara Bio Inc.

      10. 6.1.10 Thermo Fisher Scientific Inc.

      11. 6.1.11 Cell Signaling Technology Inc.

      12. 6.1.12 Miltenyi Biotec

      13. 6.1.13 QIAGEN NV

      14. 6.1.14 Claremont BioSolutions LLC

      15. 6.1.15 Microfluidics International Corporation

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Cell Lysis Market market is studied from 2018 - 2026.

The Global Cell Lysis Market is growing at a CAGR of 8.5% over the next 5 years.

The Global Cell Lysis Market is valued at 3560 Million USD in 2018.

The Global Cell Lysis Market is valued at 6200 Million USD in 2026.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Danaher Corporation are the major companies operating in Global Cell Lysis Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!